Louise Tallon Named Trinity Biotech Finance Chief

Trinity Biotech plc has welcomed Louise Tallon as chief financial officer (CFO), succeeding Des Fitzgerald, who had served as interim CFO since December 2023.
 
“We are delighted to welcome Louise, who brings extensive experience in transformation and growth within a dynamic environment,” Trinity Biotech CEO John Gillard said. “This skill set, combined with her extensive experience in the life sciences product commercialization industry, will elevate the continued development of the organization as we continue to deliver on our corporate strategy of delivering our comprehensive transformation plan and introducing our next generation continuous glucose monitor, or CGM, to global markets. With the CFO transition we also reiterate our financial guidance and intend to achieve approximately $20 million of annualized run-rate EBITDASO¹ on annualized revenues of approximately $75 million by Q2 2025.”
 
Tallon was the head of Group Finance at Inizio, a global commercialization partner in pharmaceuticals. Prior to that, she had a 16-year career with UDG Healthcare plc, where she held a number of senior finance roles of increasing responsibility. Over her 19-year career in the life sciences industry as a transformative leader, Tallon has been at the forefront of adapting and evolving finance functions in a rapidly changing business landscape. She trained as an accountant in KPMG, having earned a BBS in finance, economics and business in Trinity College, Dublin.
 
In addition to her CFO role, Tallon also will assume the duties of Chief Accounting Officer Simon Dunne, who left the company. Trinity Biotech thanks both Fitzgerald and Simon for their many contributions to the company.

“I’m excited to join the Trinity Biotech team and look forward to contributing to its vision to become a highly profitable organisation, intent on executing its development and launch of a next-generation CGM device,” Tallon stated.
 
Trinity Biotech is a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors.  The company develops, acquires, manufactures, and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market and has entered the wearable biosensor industry with the acquisition of Waveform Technologies Inc.’s biosensor assets and intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France, and the U.K. and through a network of international distributors and strategic partners in more than 75 countries worldwide. 

Reference 
¹ Earnings before interest, tax, depreciation, amortisation, share based payments from continuing operations– also excludes impairment charges and one-off items.